Tag: BD

BD Announces Clinical Trial Data for the LUTONIX® 014 Drug-Coated Balloon Below-The-Knee IDE Trial

FRANKLIN LAKES, N.J., Nov. 7, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the safety and efficacy data from the LUTONIX® Drug-Coated Balloon (DCB) IDE, level 1 clinical trial for a below-the-knee (BTK) indication. The clinical study is a prospective, global, multicenter, randomized, controlled trial comparing the […]

BD Announces Results For 2018 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2019 Guidance

FRANKLIN LAKES, N.J., Nov. 6, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.402 billion for the fourth fiscal quarter ended September 30, 2018.  This represents an increase of 39.0 percent from the prior-year period, which is primarily due to the acquisition of […]

BD Acquires TVA Medical to Advance Leadership in Solutions for Chronic Kidney Disease

FRANKLIN LAKES, N.J., July 9, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of TVA Medical, Inc., a company that develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring hemodialysis. In the U.S. alone, […]

BD Shares Progress towards Achieving 2020 Sustainability Goals

FRANKLIN LAKES, N.J., July 12, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2017 Sustainability Performance Update that focuses on four key strategic areas that support the company’s 2020 Sustainability Goals. BD’s sustainability strategy is driven by its purpose – advancing the world of health – and focuses on […]

BD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance

FRANKLIN LAKES, N.J., May 3, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018.  This represents an increase of 42.2 percent from the prior-year period, which is primarily due to the acquisition […]

BD Board Declares Dividends

FRANKLIN LAKES, N.J., April 23, 2018 /PRNewswire/ — The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.75 per common share, payable on June 29, 2018 to holders of record on June 8, 2018.  The indicated annual dividend rate is $3.00 per share.  In addition, the Board of Directors has declared […]

BD Announces Completion of Enrollment in the Lutonix 014 Drug Coated Balloon Below-the-Knee Trial

FRANKLIN LAKES, N.J., Jan. 18, 2018 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late 2018. The Lutonix BTK trial is a prospective, multicenter, randomized, […]